RALLIS CHRIS A 4
4 · FENNEC PHARMACEUTICALS INC. · Filed Oct 10, 2024
Insider Transaction Report
Form 4
RALLIS CHRIS A
Director
Transactions
- Exercise/Conversion
Common Shares
2024-10-08$2.55/sh−1,960$4,998→ 194,698 totalExercise: $2.55From: 2014-11-07Exp: 2024-11-07→ Options (1,960 underlying) - Exercise/Conversion
Common Shares
2024-10-08$2.55/sh+1,960$4,998→ 50,029 total - Sale
Common Shares
2024-10-08$4.53/sh−1,406$6,369→ 48,623 total
Footnotes (3)
- [F1]Shares acquired through the exercise of an option pursuant to a 10b5-1 plan adopted on August 17, 2023.
- [F2]Shares sold to satisfy tax obligation on option exercise.
- [F3]Represents options exercised pursuant to a 10b5-1 plan adopted on August 17, 2023.